iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone is under FDA review to treat Relapsed/refractory multiple myeloma (RRMM).
The FDA PDUFA target date for BMY (Bristol-Myers Squibb Company) is 2026-08-17 for iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone. Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is BMY's drug iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone?
iberdomide, daratumumab, and dexamethasone vs. daratumumab, bortezomib, and dexamethasone is Bristol-Myers Squibb Company's candidate under FDA review for Relapsed/refractory multiple myeloma (RRMM).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (763-PDUFA cohort, 2024-26). This is historical context by market-cap tier, not a prediction for this drug.
Decision-day move · large-cap cohortn=790 · median +0.0% · 50% up
Distribution of next-day % moves after the FDA decision for large-cap PDUFAs (2020–26). Red = down, green = up, blue = flat (±3%). Historical dispersion, not a forecast.